Phaseline

Companies › Suzhou Suncadia Biopharmaceuticals

Suzhou Suncadia Biopharmaceuticals: clinical trials, targets and expected readouts

36 active drug programs in 201 registered trials: 118 Phase 2, 53 Phase 1, 30 Phase 3; Oncology, Immunology, Other, Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Adebrelimab (SHR-1316)
Programmed cell death 1 ligand 1 inhibitor
CD274Phase 3Locally Advanced or Metastatic Urothelial Carcinoma; PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer; Advanced Biliary Tract Cancer; Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma …Dec 2026
SHR-A1811 for Injection
HER2-targeted antibody-drug conjugate
ERBB2Phase 3Advanced Colorectal Cancer; PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer; Ovarian Cancer; Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma …Dec 2026
SHR-A2009
Immunoconjugate
–Phase 3Non-small Cell Lung Cancer; Advanced Solid TumorsDec 2026
SHR-8068 Injection
TSLP receptor antagonist
TSLPPhase 3Advanced Biliary Tract Cancer; Advanced Hepatocellular Carcinoma; Advanced or Metastatic Non-small Cell Lung Cancer; Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma …Dec 2026
SHR-A1921–Phase 3Ovarian Cancer; Advanced Salivary Gland Carcinoma; Advanced Breast CancerDec 2026
Vunakizumab (SHR-1314)
Interleukin 17A inhibitor
IL17APhase 3Psoriatic Arthritis; Active Non-radiographic Axial Spondyloarthritis; Lupus Erythematosus, SystemicJan 2027
SHR-A1912
CD47 antagonist/signal regulatory protein alpha (SIRPα) blockade
CD47Phase 3Diffuse Large B-cell LymphomaMar 2027
SHR-A2102 for Injection
Forkhead box protein O1 (FOXO1) inhibitor
FOXO1Phase 3Recurrent Cervical Cancer; Locally Advanced or Metastatic Urothelial Carcinoma; Muscular Invasive Bladder Cancer (MIBC); Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaMar 2027
SHR-1501 for Injection–Phase 3Papillary-Only Non-muscle-invasive Bladder Cancer; NMIBCDec 2029
Trastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Triple Negative Breast CancerDec 2030
SHR-1701
Immunotherapy (mechanism unclear from registry)
–Phase 3Gastric or Gastroesophageal Junction Cancer–
SHR-1826
PD-L1 inhibitor
–Phase 2NSCLC; Non-Small Cell Lung Cancer; Advanced Solid Tumors; Non-small Cell Lung Cancer (NSCLC)Dec 2026
SHR-4849–Phase 2Malignant Solid Tumors; Advanced Solid TumorsDec 2026
SHR-9839(sc) for injection–Phase 2Advanced Esophageal Squamous Cell Carcinoma; Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma; Solid Tumor; Advanced Solid Tumors …Mar 2027
SHR-2017–Phase 2For Prevention of Bone Events in Patients With Bone Metastases From Solid TumorsMay 2027
SHR-A1904 for Injection–Phase 2Gastric Cancer; Biliary Tract CancerMay 2027
Bevacizumab (BP102)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 2Malignant Solid TumorsDec 2028
SHR-1681–Phase 1Malignant Solid TumorsNov 2026
SHR-1894 Injection–Phase 1DermatitisDec 2026
SHR-6914–Phase 1Prostate CancerDec 2026
SHR-7782 Injection–Phase 1Advanced MalignancyDec 2026
SHR-3821 injection–Phase 1Advanced Solid TumorsJan 2027
Adebelimab
Anti-TIGIT antibody
TIGITPhase 1Recurrent or Metastatic Cervical CancerJan 2027
SHR-4375–Phase 1Advanced Solid Tumor; Solid TumorsJan 2027
SHR-3792 Injection–Phase 1Advanced Solid TumorsFeb 2027
SHR-4506 Injection–Phase 1Malignant Tumors of AdultsFeb 2027
SHR-4642–Phase 1Advanced Solid TumorsJul 2027
SHR-9539–Phase 1Multiple MyelomaJul 2027
SHR-2524–Phase 1Advanced Unresectable Hepatocellular CarcinomaOct 2027
SHR-3079–Phase 1B-cell Non-Hodgkin LymphomaDec 2027
SHR-3276–Phase 1Advanced Solid TumorsDec 2027
SHR-5421 for Injection–Phase 1Multiple MyelomaApr 2028
SHR-4685–Phase 1Solid TumorOct 2028
SHR-4298 Injection–Phase 1Malignant Solid TumorsNov 2028
SHR-4595 for Injection–Phase 1Solid TumorDec 2029
SHR-4610–Phase 1Advanced Renal Cell CarcinomaDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04950322SHR-1701Phase 3Gastric or Gastroesophageal Junction CancerGastroenterologyMay 2024
NCT06282445Adebrelimab (SHR-1316)Phase 2Colorectal Cancer MetastaticOncologyMar 2025
NCT06765616Adebrelimab (SHR-1316)Phase 2Rectal CancerOncologyJul 2025
NCT06277791Adebrelimab (SHR-1316)Phase 2Clinical IVb Stage Oral Squamous Cell Carcinomas PatientsOncologyJul 2025
NCT07055841Adebrelimab (SHR-1316)Phase 2Squamous Cell Carcinoma of Head and NeckOncologyAug 2025
NCT06247956Adebrelimab (SHR-1316)Phase 2Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell CarcinomaOncologyDec 2025
NCT06247956SHR-8068 InjectionPhase 2Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell CarcinomaOncologyDec 2025
NCT06300424Adebrelimab (SHR-1316)Phase 2Non Small Cell Lung CancerOncologyJan 2026
NCT06199973SHR-A1811 for InjectionPhase 3Advanced Colorectal CancerOncologyApr 2026
NCT07542002Adebrelimab (SHR-1316)Phase 2Pancreatic CancerOncologyMay 2026
NCT05970666Adebrelimab (SHR-1316)Phase 2AdebrelimabOncologyNov 2026
NCT06454448Adebrelimab (SHR-1316)Phase 1Adebrelimab (SHR-1316)OncologyNov 2026
NCT06737731SHR-1681Phase 1Malignant Solid TumorsOncologyNov 2026
NCT06881290Vunakizumab (SHR-1314)Phase 1Lupus Erythematosus, SystemicImmunologyNov 2026
NCT06885814Adebrelimab (SHR-1316)Phase 2Esophageal Squamous Cell CarcinomaOncologyNov 2026
NCT06149130Adebrelimab (SHR-1316)Phase 2Breast CancerOncologyNov 2026
NCT07770113Adebrelimab (SHR-1316)Phase 2GC/GEJCOtherNov 2026
NCT07437898Adebrelimab (SHR-1316)Phase 2Esophageal Squamous Cell CarcinomaOncologyDec 2026
NCT06483282Adebrelimab (SHR-1316)Phase 2Small Cell Lung Cancer Limited StageOncologyDec 2026
NCT07123129SHR-7782 InjectionPhase 1Advanced MalignancyOncologyDec 2026
NCT06844474Adebrelimab (SHR-1316)Phase 2NSCLCOncologyDec 2026
NCT06749730Adebrelimab (SHR-1316)Phase 2Unresectable Biliary Tract CarcinomaOncologyDec 2026
NCT06454578Adebrelimab (SHR-1316)Phase 2Carcinoma, HepatocellularOncologyDec 2026
NCT06610734Adebrelimab (SHR-1316)Phase 2Small Cell Lung Cancer Extensive StageOncologyDec 2026
NCT06840002SHR-A1811 for InjectionPhase 1Ovarian CancerOncologyDec 2026
NCT06844474SHR-1826Phase 2NSCLCOncologyDec 2026
NCT06844474SHR-1826Phase 2NSCLCOncologyDec 2026
NCT06671379SHR-A2009Phase 3Non-small Cell Lung CancerOncologyDec 2026
NCT07414602SHR-1894 InjectionPhase 1DermatitisImmunologyDec 2026
NCT06443489SHR-4849Phase 1Advanced Solid TumorsOncologyDec 2026
NCT07735377SHR-6914Phase 1Prostate CancerOncologyDec 2026
NCT06465563Adebrelimab (SHR-1316)Phase 2Biliary Tract CancerOncologyDec 2026
NCT06485544Adebrelimab (SHR-1316)Phase 2Small Cell Lung Cancer (SCLC)OncologyDec 2026
NCT07141264Adebrelimab (SHR-1316)Phase 2SCLC,Extensive StageOncologyDec 2026
NCT06741020Adebrelimab (SHR-1316)Phase 1Hepatocellular Carcinoma (HCC)OncologyDec 2026
NCT06465563SHR-8068 InjectionPhase 2Biliary Tract CancerOncologyDec 2026
NCT05924256SHR-A1921Phase 2Advanced Salivary Gland CarcinomaOncologyDec 2026
NCT05114759SHR-A2009Phase 1Advanced Solid TumorsOncologyDec 2026
NCT06620848Adebrelimab (SHR-1316)Phase 2Biliary Tract CancerOncologyDec 2026
NCT05076682Adebrelimab (SHR-1316)Phase 2Triple-negative Breast CancerOncologyDec 2026
NCT06700421Adebrelimab (SHR-1316)Phase 2Unresectable Locally Advanced Non-small Cell Lung CancerOncologyDec 2026
NCT06418594Adebrelimab (SHR-1316)Phase 2HER2-negative Breast Cancer Brain MetastasesOncologyDec 2026
NCT06500208Adebrelimab (SHR-1316)Phase 2Breast CancerOncologyDec 2026
NCT06776770Adebrelimab (SHR-1316)Phase 1Gastric CancerOncologyDec 2026
NCT06394492SHR-A1921Phase 3Ovarian CancerOncologyDec 2026
NCT06091124Adebrelimab (SHR-1316)Phase 2Neuroendocrine Carcinoma of the BladderOncologyJan 2027
NCT06618651SHR-3821 injectionPhase 1Advanced Solid TumorsOncologyJan 2027
NCT06208462Adebrelimab (SHR-1316)Phase 2Intrahepatic CholangiocarcinomaOncologyJan 2027
NCT06859775SHR-A1811 for InjectionPhase 1Recurrent or Metastatic Cervical CancerOncologyJan 2027
NCT06859775SHR-8068 InjectionPhase 1Recurrent or Metastatic Cervical CancerOncologyJan 2027
NCT07298772SHR-4375Phase 1Advanced Solid TumorOncologyJan 2027
NCT06859775AdebelimabPhase 1Recurrent or Metastatic Cervical CancerOncologyJan 2027
NCT06640257Vunakizumab (SHR-1314)Phase 3Psoriatic ArthritisImmunologyJan 2027
NCT06907628SHR-3792 InjectionPhase 1Advanced Solid TumorsOncologyFeb 2027
NCT07068932SHR-4506 InjectionPhase 1Malignant Tumors of AdultsOncologyFeb 2027
NCT07452601Adebrelimab (SHR-1316)Phase 2Esophageal Squamous Cell CarcinomaOncologyFeb 2027
NCT06298968Adebrelimab (SHR-1316)Phase 2Intrahepatic CholangiocarcinomaOncologyFeb 2027
NCT06467617Adebrelimab (SHR-1316)Phase 2Non Small Cell Lung CancerOncologyMar 2027
NCT06296563Adebrelimab (SHR-1316)Phase 2Intrahepatic CholangiocarcinomaOncologyMar 2027
NCT07059221Adebrelimab (SHR-1316)Phase 1Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaOncologyMar 2027

The 60 nearest readouts of 201 trials; the rest in the app.

Targets

ERBB2 (2) CD274 (1) TSLP (1) IL17A (1) CD47 (1) FOXO1 (1) VEGFA (1) TIGIT (1)

Companies with the same targets

Beijing Biotech Roche Pfizer AstraZeneca Shenyang Sunshine Pharmaceutical Shanghai Henlius Biotech Jiangsu HengRui Medicine Biocad Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Sichuan Baili Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.